MK-4541 is an orally active, selective androgen receptor (AR) modulator that serves as an antagonist to inhibit 5α-reductase. It effectively inhibits proliferation and induces apoptosis in AR-positive prostate cancer cells, significantly reducing the growth of R3327-G prostate tumors in a xenograft mouse model.